ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution
Drug: Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution
Drug: Brimonidine 0.2% ophthalmic solution

First Posted Date: 2008-04-03

Last Posted Date: 2008-04-03

Lead Sponsor: Allergan

Target Recruit Count: 432

Registration Number: NCT00652106

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: Bimatoprost 0.01% ophthalmic solution
Drug: Bimatoprost 0.015% formulation 1 ophthalmic solution
Drug: Bimatoprost 0.015% formulation 2 ophthalmic solution
Drug: Bimatoprost 0.02% ophthalmic solution
Drug: Bimatoprost 0.03% ophthalmic solution

First Posted Date: 2008-04-03

Last Posted Date: 2008-04-03

Lead Sponsor: Allergan

Target Recruit Count: 249

Registration Number: NCT00652496

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: Bimatoprost 0.01% Ophthalmic Solution
Drug: Bimatoprost 0.03% Ophthalmic Solution
Drug: Bimatoprost Vehicle Ophthalmic Solution

First Posted Date: 2008-04-03

Last Posted Date: 2008-04-03

Lead Sponsor: Allergan

Target Recruit Count: 111

Registration Number: NCT00651859

Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

Phase 3

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution
Drug: Concurrent brimonidine 0.2% and 0.5% timolol

First Posted Date: 2008-04-03

Last Posted Date: 2008-04-03

Lead Sponsor: Allergan

Target Recruit Count: 604

Registration Number: NCT00651612

Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: Brimonidine ophthalmic solution 0.1%
Drug: Brimonidine ophthalmic solution 0.2%

First Posted Date: 2008-04-03

Last Posted Date: 2008-04-03

Lead Sponsor: Allergan

Target Recruit Count: 433

Registration Number: NCT00652483

Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers

Phase 2

Completed

Conditions: Acute Bacterial Corneal Ulcers
Bacterial Keratitis

Interventions: Drug: Gatifloxacin 0.3% ophthalmic solution
Drug: Ciprofloxacin 0.3% ophthalmic solution

First Posted Date: 2008-04-03

Last Posted Date: 2008-07-29

Lead Sponsor: Allergan

Target Recruit Count: 129

Registration Number: NCT00651586

Safety and Blood Level Study of Unit Dose Budesonide

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Budesonide Inhalation Suspension
Drug: MAP0010 low dose
Drug: MAP0010 intermediate dose
Drug: MAP0010 high dose

First Posted Date: 2008-03-03

Last Posted Date: 2014-01-09

Lead Sponsor: Allergan

Target Recruit Count: 16

Registration Number: NCT00627679

Locations: 🇦🇺
Q-Pharm Pty Limited, Brisbane, Queensland, Australia

Phase 3 Study of MAP0004 in Adult Migraineurs

Phase 3

Completed

Conditions: Migraine Disorders

Interventions: Drug: MAP0004
Drug: Placebo

First Posted Date: 2008-02-26

Last Posted Date: 2014-01-09

Lead Sponsor: Allergan

Target Recruit Count: 902

Registration Number: NCT00623636

Locations: 🇺🇸
Swedish Pain and Headache Clinic, Seattle, Washington, United States

Surveillance of Ocular Surface Flora (SURFACE)

Completed

Conditions: Cataract

First Posted Date: 2008-02-22

Last Posted Date: 2019-04-26

Lead Sponsor: Allergan

Target Recruit Count: 399

Registration Number: NCT00621933

Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients

Phase 2

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)
Drug: Artificial Tears REFRESH ENDURA®

First Posted Date: 2008-02-08

Last Posted Date: 2011-12-20

Lead Sponsor: Allergan

Target Recruit Count: 137

Registration Number: NCT00611403

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy